BiomX

Company Overview

Snapshot

Founded in May 2015 by Eran Elinav, Rotem Sorek, and Tim Lu, BiomX operates with 51–200 employees. The company has raised a total of $146.5M across 11 funding rounds from 15 investors. In April 2026, BiomX acquired Zorronet, an autonomous AI command-and-control platform, expanding its presence in security and defense markets.

Business overview

BiomX is a clinical-stage microbiome company specializing in developing natural and engineered phage cocktails to target and eliminate bacteria in chronic diseases. Its therapeutic focus areas include cystic fibrosis, atopic dermatitis, inflammatory bowel disease, primary sclerosing cholangitis, and colorectal cancer. The company leverages computational and synthetic biology platforms, alongside research from the Weizmann Institute of Science and MIT, to discover and validate proprietary bacterial targets and customize phage compositions. BiomX is also expanding into security and defense markets by identifying and commercializing technologies that address operational needs in national security, emergency response, and critical infrastructure protection.

Strategic signal

In April 2026, BiomX acquired Zorronet, an autonomous AI command-and-control platform, and Dr. Frucht Systems. This strategic move signals a significant diversification beyond its core microbiome therapeutics into the defense and security sectors, leveraging AI for real-time command and control. For investors, this indicates a potential new growth vector and a broader market opportunity, moving beyond the traditional biotech landscape into a high-demand area with evolving operational needs.

Company Intelligence Q&A

What was a significant recent acquisition by BiomX?

In April 2026, BiomX acquired Zorronet, an autonomous AI command-and-control platform, to expand its presence in security and defense markets.

What was another acquisition made by BiomX in April 2026?

In April 2026, BiomX also acquired Dr. Frucht Systems, further accelerating its defense technology buildout.

When did BiomX merge with Adaptive Phage Therapeutics?

In March 2024, BiomX announced its entry into a merger agreement with Adaptive Phage Therapeutics, accompanied by a concurrent $50 million financing.

What were the results of the Phase 1b/2a trial for BX004 in November 2023?

In November 2023, BiomX announced positive topline results from Part 2 of the Phase 1b/2a trial evaluating BX004 for the treatment of chronic pulmonary infections in patients with cystic fibrosis.

Which investors participated in a February 2023 private placement for BiomX?

In February 2023, BiomX announced a private placement with participation from OrbiMed and Cystic Fibrosis Foundation.